Amgen Inc.
ANTIBODIES WITH MODULATED GLYCAN PROFILES
Last updated:
Abstract:
This invention relates to recombinantly-expressed denosumab molecules and methods for modulating glycan profiles of denosumab molecules.
Status:
Application
Type:
Utility
Filling date:
30 Apr 2019
Issue date:
4 Mar 2021